SK282000B6 - Trojfázová farmaceutická forma s konštantným a riadeným uvoľňovaním amorfnej účinnej zložky a spôsob jej prípravy - Google Patents

Trojfázová farmaceutická forma s konštantným a riadeným uvoľňovaním amorfnej účinnej zložky a spôsob jej prípravy Download PDF

Info

Publication number: SK282000B6
Authority: SK; Slovakia
Prior art keywords: phase; pharmaceutical form; active ingredient; cellulose ether; polyvinylpyrrolidone
Prior art date: 1995-05-19

Application number

SK1534-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK153497A3 (en

Inventor

Janez Ker

Ljubomira Barbara Rebi�

Bojan Kofler

Original Assignee

Lek, Tovarna Farmacevtskih In Kemi�Nih Izdelkov, D. D.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-19

Filing date

1996-05-17

Publication date

2001-10-08

1996-05-17 Application filed by Lek, Tovarna Farmacevtskih In Kemi�Nih Izdelkov, D. D. filed Critical Lek, Tovarna Farmacevtskih In Kemi�Nih Izdelkov, D. D.

1998-04-08 Publication of SK153497A3 publication Critical patent/SK153497A3/sk

2001-10-08 Publication of SK282000B6 publication Critical patent/SK282000B6/sk

Links

239000004480 active ingredient Substances 0.000 title claims abstract description 102
238000013270 controlled release Methods 0.000 title abstract description 30
238000002360 preparation method Methods 0.000 title description 9
229920003086 cellulose ether Polymers 0.000 claims abstract description 57
239000000203 mixture Substances 0.000 claims abstract description 52
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 50
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 50
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 49
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 49
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 47
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 47
-1 hydroxypropylmethylcellulose ester Chemical class 0.000 claims abstract description 44
239000011248 coating agent Substances 0.000 claims abstract description 35
238000000576 coating method Methods 0.000 claims abstract description 35
239000004094 surface-active agent Substances 0.000 claims abstract description 17
150000003626 triacylglycerols Chemical class 0.000 claims abstract description 17
238000013268 sustained release Methods 0.000 claims abstract description 12
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims abstract description 11
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims abstract description 11
239000012730 sustained-release form Substances 0.000 claims abstract description 11
LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 claims abstract description 10
JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 claims abstract description 10
229920003145 methacrylic acid copolymer Polymers 0.000 claims abstract description 10
239000003112 inhibitor Substances 0.000 claims abstract description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 40
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
229960001597 nifedipine Drugs 0.000 claims description 29
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 29
239000000454 talc Substances 0.000 claims description 20
229910052623 talc Inorganic materials 0.000 claims description 20
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
229920000642 polymer Polymers 0.000 claims description 15
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 14
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 10
239000000654 additive Substances 0.000 claims description 9
239000008187 granular material Substances 0.000 claims description 9
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 8
235000019359 magnesium stearate Nutrition 0.000 claims description 8
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 8
239000001069 triethyl citrate Substances 0.000 claims description 8
235000013769 triethyl citrate Nutrition 0.000 claims description 8
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 8
239000001856 Ethyl cellulose Substances 0.000 claims description 7
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
235000019325 ethyl cellulose Nutrition 0.000 claims description 7
229920001249 ethyl cellulose Polymers 0.000 claims description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
239000003960 organic solvent Substances 0.000 claims description 7
239000000049 pigment Substances 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
239000004408 titanium dioxide Substances 0.000 claims description 7
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical group Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 claims description 6
229960002289 nicardipine hydrochloride Drugs 0.000 claims description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 5
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
229920000609 methyl cellulose Polymers 0.000 claims description 5
235000010981 methylcellulose Nutrition 0.000 claims description 5
239000001923 methylcellulose Substances 0.000 claims description 5
229940068917 polyethylene glycols Drugs 0.000 claims description 5
239000008107 starch Substances 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 4
235000021355 Stearic acid Nutrition 0.000 claims description 4
239000001087 glyceryl triacetate Substances 0.000 claims description 4
235000013773 glyceryl triacetate Nutrition 0.000 claims description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
239000008117 stearic acid Substances 0.000 claims description 4
229960002622 triacetin Drugs 0.000 claims description 4
229920003169 water-soluble polymer Polymers 0.000 claims description 4
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical group CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
229960003580 felodipine Drugs 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
108090000312 Calcium Channels Proteins 0.000 claims description 2
102000003922 Calcium Channels Human genes 0.000 claims description 2
108010010803 Gelatin Proteins 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
235000021314 Palmitic acid Nutrition 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
239000000150 Sympathomimetic Substances 0.000 claims description 2
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical group OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
229940035674 anesthetics Drugs 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
230000000844 anti-bacterial effect Effects 0.000 claims description 2
229940125681 anticonvulsant agent Drugs 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000002221 antipyretic Substances 0.000 claims description 2
229940125716 antipyretic agent Drugs 0.000 claims description 2
239000003899 bactericide agent Substances 0.000 claims description 2
229940124630 bronchodilator Drugs 0.000 claims description 2
239000000168 bronchodilator agent Substances 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
229940124558 contraceptive agent Drugs 0.000 claims description 2
239000003433 contraceptive agent Substances 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
229940030606 diuretics Drugs 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
230000002526 effect on cardiovascular system Effects 0.000 claims description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
229960002297 fenofibrate Drugs 0.000 claims description 2
239000007888 film coating Substances 0.000 claims description 2
238000009501 film coating Methods 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
239000003193 general anesthetic agent Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
230000003345 hyperglycaemic effect Effects 0.000 claims description 2
239000003326 hypnotic agent Substances 0.000 claims description 2
230000000147 hypnotic effect Effects 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
125000005395 methacrylic acid group Chemical group 0.000 claims description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
229920001983 poloxamer Polymers 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
230000001975 sympathomimetic effect Effects 0.000 claims description 2
229940064707 sympathomimetics Drugs 0.000 claims description 2
239000004599 antimicrobial Substances 0.000 claims 5
150000004665 fatty acids Chemical class 0.000 claims 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims 1
239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
239000002160 alpha blocker Substances 0.000 claims 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 1
230000001754 anti-pyretic effect Effects 0.000 claims 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
239000003158 myorelaxant agent Substances 0.000 claims 1
230000001670 myorelaxant effect Effects 0.000 claims 1
239000000734 parasympathomimetic agent Substances 0.000 claims 1
230000001499 parasympathomimetic effect Effects 0.000 claims 1
229940005542 parasympathomimetics Drugs 0.000 claims 1
229920001296 polysiloxane Polymers 0.000 claims 1
229940125723 sedative agent Drugs 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
239000011782 vitamin Substances 0.000 claims 1
229940088594 vitamin Drugs 0.000 claims 1
229930003231 vitamin Natural products 0.000 claims 1
235000013343 vitamin Nutrition 0.000 claims 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
238000002425 crystallisation Methods 0.000 abstract description 5
230000008025 crystallization Effects 0.000 abstract description 5
238000010521 absorption reaction Methods 0.000 abstract description 4
229940117841 methacrylic acid copolymer Drugs 0.000 abstract description 2
239000003826 tablet Substances 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
238000004090 dissolution Methods 0.000 description 19
239000010408 film Substances 0.000 description 18
238000009472 formulation Methods 0.000 description 13
238000000034 method Methods 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
238000007922 dissolution test Methods 0.000 description 8
239000002609 medium Substances 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
238000004445 quantitative analysis Methods 0.000 description 8
238000000870 ultraviolet spectroscopy Methods 0.000 description 8
210000004051 gastric juice Anatomy 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
229920000053 polysorbate 80 Polymers 0.000 description 7
239000000126 substance Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000005303 weighing Methods 0.000 description 6
239000000969 carrier Substances 0.000 description 5
NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 5
239000000243 solution Substances 0.000 description 5
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000004203 carnauba wax Substances 0.000 description 4
235000013869 carnauba wax Nutrition 0.000 description 4
239000013078 crystal Substances 0.000 description 4
229940096464 nifedipine 60 mg Drugs 0.000 description 4
230000008569 process Effects 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
229940032147 starch Drugs 0.000 description 4
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
229920003091 Methocel™ Polymers 0.000 description 3
229920003096 Methocel™ K100M Polymers 0.000 description 3
239000000945 filler Substances 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000007939 sustained release tablet Substances 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920003080 Povidone K 25 Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004141 Sodium laurylsulphate Substances 0.000 description 2
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000002902 bimodal effect Effects 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Polymers [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229920000151 polyglycol Polymers 0.000 description 2
239000010695 polyglycol Substances 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
239000003204 tranquilizing agent Substances 0.000 description 2
230000002936 tranquilizing effect Effects 0.000 description 2
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
229920003085 Kollidon® CL Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
YGFWVRVLSSMBGH-UHFFFAOYSA-N [Li]CCCO Chemical compound [Li]CCCO YGFWVRVLSSMBGH-UHFFFAOYSA-N 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
229910000323 aluminium silicate Inorganic materials 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Polymers [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000009500 colour coating Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013039 cover film Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
XTAXEJIXAUYSGM-UHFFFAOYSA-N ethyl acetate;propan-2-yl acetate Chemical compound CCOC(C)=O.CC(C)OC(C)=O XTAXEJIXAUYSGM-UHFFFAOYSA-N 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Polymers CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Polymers [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Polymers [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007962 solid dispersion Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1
239000001993 wax Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Polymers [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1534-97A 1995-05-19 1996-05-17 Trojfázová farmaceutická forma s konštantným a riadeným uvoľňovaním amorfnej účinnej zložky a spôsob jej prípravy SK282000B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SI9500173A SI9500173B (sl)	1995-05-19	1995-05-19	Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
PCT/SI1996/000012 WO1996036318A2 (en)	1995-05-19	1996-05-17	Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application

Publications (2)

Publication Number	Publication Date
SK153497A3 SK153497A3 (en)	1998-04-08
SK282000B6 true SK282000B6 (sk)	2001-10-08

Family

ID=20431627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1534-97A SK282000B6 (sk)	1995-05-19	1996-05-17	Trojfázová farmaceutická forma s konštantným a riadeným uvoľňovaním amorfnej účinnej zložky a spôsob jej prípravy

Country Status (15)

Country	Link
US (1)	US6042847A (pl)
EP (1)	EP0827397B1 (pl)
JP (1)	JPH11505542A (pl)
AT (1)	ATE205081T1 (pl)
AU (1)	AU698360B2 (pl)
CZ (1)	CZ288598B6 (pl)
DE (1)	DE69615017D1 (pl)
HU (1)	HUP9901457A3 (pl)
PL (1)	PL184183B1 (pl)
RO (1)	RO117148B1 (pl)
RU (1)	RU2161956C2 (pl)
SI (1)	SI9500173B (pl)
SK (1)	SK282000B6 (pl)
UA (1)	UA42062C2 (pl)
WO (1)	WO1996036318A2 (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
IT1284604B1 (it) *	1996-09-27	1998-05-21	Roberto Valducci	Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2783421B1 (fr) *	1998-09-17	2000-11-24	Cll Pharma	Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
IL143197A0 (en) *	1998-11-20	2002-04-21	Rtp Pharma Inc	Dispersible phospholipid stabilized microparticles
US6838091B2 (en)	1998-12-18	2005-01-04	Abbott Laboratories	Formulations comprising lipid-regulating agents
US7014864B1 (en)	1998-12-18	2006-03-21	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6814977B1 (en)	1998-12-18	2004-11-09	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6706283B1 (en)	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6719999B2 (en)	1999-03-31	2004-04-13	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6465011B2 (en)	1999-05-29	2002-10-15	Abbott Laboratories	Formulations comprising lipid-regulating agents
US8895064B2 (en)	1999-06-14	2014-11-25	Cosmo Technologies Limited	Controlled release and taste masking oral pharmaceutical composition
WO2000076478A1 (en)	1999-06-14	2000-12-21	Cosmo S.P.A.	Controlled release and taste masking oral pharmaceutical compositions
US6982281B1 (en)	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920558D0 (en) *	1999-08-31	1999-11-03	Bradford Particle Design Ltd	Methods for particle formation and their products
KR20020038941A (ko)	1999-10-11	2002-05-24	디. 제이. 우드, 스피겔 알렌 제이	포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
EP1175205B1 (en) *	1999-11-12	2006-06-14	Abbott Laboratories	Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
RU2169557C1 (ru) *	1999-12-22	2001-06-27	Александр Афанасьевич Яремчук	Сироп амброксола для лечения бронхопульмональных заболеваний
DE10026698A1 (de) *	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
US20020058065A1 (en) *	2000-09-20	2002-05-16	Pol-Henri Guivarc'h	Insoluble drug particle compositions with improved fasted-fed effects
FR2819720B1 (fr) *	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
US20080058424A1 (en) *	2002-05-23	2008-03-06	Cephalon, Inc.	Novel pharmaceutical formulations of modafinil
EP1269994A3 (en) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
JP2005522424A (ja)	2002-02-01	2005-07-28	ファイザー・プロダクツ・インク	コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
US7229644B2 (en) *	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
US7445796B2 (en) *	2002-08-19	2008-11-04	L. Perrigo Company	Pharmaceutically active particles of a monomodal particle size distribution and method
US20040116532A1 (en) *	2002-09-13	2004-06-17	Craig Heacock	Pharmaceutical formulations of modafinil
EP1400835B1 (en) *	2002-09-17	2011-11-16	Nippon Telegraph And Telephone Corporation	Semiconductor optical modulator and laser with such optical modulator
US20080051411A1 (en) *	2002-12-17	2008-02-28	Cink Russell D	Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
EP1572190B1 (en) *	2002-12-17	2007-04-18	Abbott GmbH & Co. KG	Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
KR100598326B1 (ko)	2004-04-10	2006-07-10	한미약품 주식회사	ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
CN101810882B (zh) *	2004-09-24	2013-07-24	Hi-Lex株式会社	机体硬组织或软组织诱导性支架材料
EP1830822A1 (en) *	2004-12-24	2007-09-12	LEK Pharmaceuticals D.D.	Stable pharmaceutical composition comprising an active substance in the form of solid solution
EP1785133A1 (en)	2005-11-10	2007-05-16	Laboratoires Fournier S.A.	Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
US20070190145A1 (en) *	2006-01-27	2007-08-16	Eurand, Inc.	Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
EP1837020A1 (en)	2006-03-24	2007-09-26	Bioalliance Pharma	Mucosal bioadhesive slow release carrier for delivering active principles
US9254266B2 (en) *	2007-03-21	2016-02-09	Wisconsin Alumni Research Foundation	Inhibiting surface enhanced crystallization of amorphous pharmaceuticals with ultrathin coatings
DE102007048705A1 (de) *	2007-10-11	2009-04-16	Bayer Healthcare Ag	Amorphe Formulierung
WO2009085766A2 (en) *	2007-12-19	2009-07-09	Mutual Pharmaceutical Company, Inc.	Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090187040A1 (en) *	2008-01-18	2009-07-23	Tong Sun	Fenofibric acid polymorphs; methods of making; and methods of use thereof
US8861813B2 (en) *	2008-03-13	2014-10-14	Mallinckrodt Llc	Multi-function, foot-activated controller for imaging system
US20100159001A1 (en) *	2008-12-19	2010-06-24	Cardinal John R	Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) *	2008-12-19	2010-06-24	Aaipharma Services Corp.	Extended-release pharmaceutical formulations
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
UA118080C2 (uk) *	2009-06-11	2018-11-26	Еббві Айрленд Анлімітед Компані	Противірусні сполуки
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US10154964B2 (en)	2011-09-07	2018-12-18	Cosmo Technologies Limited	Controlled release and taste masking oral pharmaceutical composition
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
WO2015038376A1 (en) *	2013-09-11	2015-03-19	3M Innovative Properties Company	Coating compositions, dental structures thereof and methods for generating contrast
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
TWI525103B (zh)	2014-12-29	2016-03-11	財團法人工業技術研究院	改質纖維素與及應用其之複合材料
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
EP3824296A4 (en)	2018-07-20	2022-04-27	Lipocine Inc.	LIVER DISEASE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1579818A (en) *	1977-06-07	1980-11-26	Yamanouchi Pharma Co Ltd	Nifedipine-containing solid preparation composition
US4259314A (en) *	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
US4327725A (en) *	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4783337A (en) *	1983-05-11	1988-11-08	Alza Corporation	Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) *	1983-05-11	1986-09-16	Alza Corporation	Osmotic device with dual thermodynamic activity
WO1987000044A1 (en) *	1985-07-02	1987-01-15	The Upjohn Company	Therapeutic formulations with bimodal release characteristics
US5015479A (en) *	1987-02-02	1991-05-14	Seamus Mulligan	Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4786503A (en) *	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
DE3720757A1 (de) *	1987-06-24	1989-01-05	Bayer Ag	Dhp-manteltablette
US4792452A (en) *	1987-07-28	1988-12-20	E. R. Squibb & Sons, Inc.	Controlled release formulation
US5009895A (en) *	1990-02-02	1991-04-23	Merck & Co., Inc.	Sustained release with high and low viscosity HPMC
BE1004243A3 (fr) *	1990-05-17	1992-10-20	Europharmaceuticals Sa	Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation.
DE4226753A1 (de) *	1992-08-13	1994-02-17	Basf Ag	Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
IT1264517B1 (it) *	1993-05-31	1996-09-24	Ekita Investments Nv	Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
HU213407B (en) *	1993-12-09	1997-06-30	Egyt Gyogyszervegyeszeti Gyar	Process for producing tablet with diffusive-osmotic release

1995
- 1995-05-19 SI SI9500173A patent/SI9500173B/sl not_active IP Right Cessation
1996
- 1996-05-17 RO RO97-02138A patent/RO117148B1/ro unknown
- 1996-05-17 EP EP96915292A patent/EP0827397B1/en not_active Expired - Lifetime
- 1996-05-17 HU HU9901457A patent/HUP9901457A3/hu unknown
- 1996-05-17 SK SK1534-97A patent/SK282000B6/sk unknown
- 1996-05-17 UA UA97115512A patent/UA42062C2/uk unknown
- 1996-05-17 WO PCT/SI1996/000012 patent/WO1996036318A2/en not_active Ceased
- 1996-05-17 CZ CZ19973655A patent/CZ288598B6/cs not_active IP Right Cessation
- 1996-05-17 PL PL96323487A patent/PL184183B1/pl unknown
- 1996-05-17 AU AU57103/96A patent/AU698360B2/en not_active Ceased
- 1996-05-17 AT AT96915292T patent/ATE205081T1/de not_active IP Right Cessation
- 1996-05-17 DE DE69615017T patent/DE69615017D1/de not_active Expired - Lifetime
- 1996-05-17 RU RU97120754/14A patent/RU2161956C2/ru not_active IP Right Cessation
- 1996-05-17 JP JP8534769A patent/JPH11505542A/ja active Pending
- 1996-05-17 US US08/945,984 patent/US6042847A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PL184183B1 (pl)	2002-09-30
WO1996036318A3 (en)	1997-01-16
AU698360B2 (en)	1998-10-29
HUP9901457A3 (en)	2000-06-28
WO1996036318A2 (en)	1996-11-21
HUP9901457A2 (hu)	1999-08-30
PL323487A1 (en)	1998-03-30
EP0827397A2 (en)	1998-03-11
SI9500173B (sl)	2002-02-28
CZ288598B6 (cs)	2001-07-11
AU5710396A (en)	1996-11-29
CZ365597A3 (cs)	1998-04-15
UA42062C2 (uk)	2001-10-15
ATE205081T1 (de)	2001-09-15
RO117148B1 (ro)	2001-11-30
JPH11505542A (ja)	1999-05-21
US6042847A (en)	2000-03-28
DE69615017D1 (de)	2001-10-11
SI9500173A (en)	1996-12-31
RU2161956C2 (ru)	2001-01-20
EP0827397B1 (en)	2001-09-05
SK153497A3 (en)	1998-04-08

Publication	Publication Date	Title
SK282000B6 (sk)	2001-10-08	Trojfázová farmaceutická forma s konštantným a riadeným uvoľňovaním amorfnej účinnej zložky a spôsob jej prípravy
US4753801A (en)	1988-06-28	Sustained release tablets
ES2273790T3 (es)	2007-05-16	Composicion farmaceutica de liberacion sostenida.
JP5322039B2 (ja)	2013-10-23	フェニルアラニン誘導体の徐放性経口投与製剤
SK283082B6 (sk)	2003-02-04	Tuhá perorálna aplikačná forma s regulovaným uvoľňovaním
WO2009034541A9 (en)	2009-12-30	Controlled release pharmaceutical dosage forms of trimetazidine
KR20220151016A (ko)	2022-11-11	토파시티닙 경구용 지속 방출 투여 형태
EP0811374A1 (en)	1997-12-10	Combination dosage form comprising cetirizine and pseudoephedrine
WO2008064202A2 (en)	2008-05-29	Modified-release formulations of calcium receptor-active compounds
MX2007001138A (es)	2007-04-19	Comprimido farmaceutico multicapa para la liberacion controlada de ingredientes activos con solubilidad muy dependiente del ph.
JP3677156B2 (ja)	2005-07-27	医薬
US20130323309A1 (en)	2013-12-05	Sustained Release Composition of Memantine
CA2560812A1 (en)	2005-10-13	Coated tablet formulation and method
EP2391353A1 (en)	2011-12-07	Pharmaceutical compositions of trimetazidine
EP3796908B1 (en)	2023-05-10	Controlled release propiverine formulations
EP3331502A1 (en)	2018-06-13	Controlled release propiverine formulations
ES2860694T3 (es)	2021-10-05	Composición farmacéutica de liberación sostenida que contiene rivastigmina
TWI434682B (zh)	2014-04-21	用以製備控制釋放口服劑型的配方及方法
RU2854425C1 (ru)	2026-01-12	Новая фармацевтическая композиция тамсулозина и солифенацина в виде множества частиц
WO2021220133A1 (en)	2021-11-04	Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
CN118265524A (zh)	2024-06-28	黄酮哌酯的控制释放制剂及其制备方法
JP2005213220A (ja)	2005-08-11	放出制御医薬組成物およびこれを用いる製剤
JP2008115083A (ja)	2008-05-22	塩酸トラマドール含有コーティング顆粒